Yes, but only in narrow and specific ways: a familial Alzheimer's panel can confirm a known mutation in a family, open the door to prevention trials, and shape who gets tested next. What it will not do is set your treatment plan, because the drug decisions that genotype actually governs are made inside a clinic, alongside imaging, staging, and counseling you cannot order from home.
A "familial Alzheimer's genetic panel" tests the three genes that cause autosomal dominant Alzheimer's disease — APP, PSEN1 and PSEN2 — where a single inherited variant causes the disease, usually before age 65. That is a different test from APOE genotyping, which reports a risk factor, not a cause, and which has its own role in drug safety. Confusing the two is the most common reason people arrive at a memory clinic with a result that answers a question they were not asking.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Which gene test answers which question
- Where APOE genotype genuinely changes a treatment decision
- Why a result ordered on your own may not be usable
- What a confirmed familial mutation unlocks
- Risks of testing outside a clinical pathway
- Frequently Asked Questions
Which gene test answers which question
The causal panel and the risk test are not interchangeable. APP, PSEN1 and PSEN2 variants cause disease with near-certainty; APOE ε4 raises the odds and predicts a specific drug side effect. A result from one tells you nothing about the other. The population affected by the causal panel is small.
Early-onset Alzheimer's is roughly 5–10% of all cases, and only about 10% of those are autosomal dominant, according to a 2025 review in Alzheimer's Research & Therapy. The same review notes that in one French population study, PSEN1 and APP together explained 71% of autosomal-dominant early-onset families — so a negative panel in a family with a strong early-onset history does not fully close the question. Consumer genetic reports do not fill the gap. The Alzheimer's Association's summary of the FDA's April 2017 authorization of 23andMe's genetic health risk reports explains that the Alzheimer's report covers late-onset risk, not diagnosis, and reads only APOE ε4. It does not sequence APP, PSEN1 or PSEN2 at all.
Where APOE genotype genuinely changes a treatment decision
The anti-amyloid antibodies are where a genetic result has direct, numeric consequences. Both approved drugs require APOE ε4 testing before the first infusion, because the genotype predicts ARIA — amyloid-related imaging abnormalities, which are brain swelling or small bleeds seen on MRI. The numbers are not subtle. In the CLARITY AD trial, ARIA-E occurred in 5.4% of ApoE ε4 noncarriers, 10.9% of heterozygotes and 32.6% of homozygotes treated with lecanemab, per the Alzheimer's Association's clinician toolkit on APOE and lecanemab.
The FDA label for Leqembi, in its 2025 revision, states that ε4 homozygotes — about 15% of Alzheimer's patients — have a higher incidence of symptomatic, serious and severe radiographic ARIA than heterozygotes and noncarriers. Donanemab sits in a similar place with one difference worth knowing. Kisunla carries a boxed ARIA warning updated in July 2025 and also directs that APOE ε4 testing be done before starting, while Lilly's prescriber materials state that ARIA *management* recommendations do not differ by carrier status, with enhanced vigilance in the first 24 weeks. In other words, genotype informs the decision to treat and the conversation about risk, not a separate monitoring protocol.
Why a result ordered on your own may not be usable
Two practical limits apply to a genotype you bring in from outside. The first is regulatory: Lilly's HCP page for Kisunla states that no FDA-authorized test for detecting ApoE ε4 alleles for this purpose is currently available, and that available tests may vary in accuracy and design. A prescriber may reasonably want the result repeated through their own laboratory. The second is the counseling requirement.
The Leqembi label directs that prescribers discuss ARIA risk across genotypes, and the implications of results, *before* testing. A number learned alone, weeks before an appointment, is the same number without the part that makes it usable. The label also records the option many people overlook: patients who decline APOE testing may still be treated, but their homozygote status will be unknown. Declining is a choice with a stated consequence, not a disqualification.
What a confirmed familial mutation unlocks
For families with a known APP, PSEN1 or PSEN2 variant, the strongest argument for testing is access, not prognosis. The Dominantly Inherited Alzheimer Network Trials Unit runs prevention studies in exactly this group, and DIAN-TU relaunched DIAN-TU-002 with remternetug (NCT06647498), enrolling people over 18 who carry or are at risk for one of those mutations with a CDR Global score of 0 — meaning no clinical impairment. DIAN-TU's own FAQ describes a staged approach to disclosure: participants may enter Stage 1 without knowing their genetic status, but must learn it for Stage 2.
That matters for anyone who wants to act without being told their result immediately. It is one of the few routes that separates the two decisions. Enrollment while cognitively normal is the point. If trial access is part of your reason for testing, the timing question changes from "before my clinic visit?" to "while there is still a window," which is a different and more urgent calculation.
Risks of testing outside a clinical pathway
Two risks are structural rather than medical. The first is insurance. The Genetic Information Nondiscrimination Act does not cover life, long-term care or disability insurance, as Tenenbaum and Goodman set out in Personalized Medicine, so a familial panel result can be used in underwriting those policies, with only patchwork state laws filling the gap. Policies are generally easier to secure before a result exists.
The second is the counseling protocol. The joint ACMG/NSGC practice guideline on Alzheimer genetic counseling (Goldman et al., Genetics in Medicine 2011) recommends a Huntington-style protocol with formal pre-test counseling for asymptomatic at-risk relatives, advises against direct-to-consumer APOE testing, and states that testing children for Alzheimer's should not occur. NSGC's Dementia Workgroup has approval to update it. A short checklist before you order anything:.
- Confirm which genes the panel actually reads — APP, PSEN1 and PSEN2, or only APOE.
- Ask whether the ordering clinic will accept an outside laboratory's result.
- Settle life, disability and long-term care coverage first if you intend to buy any.
- Arrange pre-test counseling, not just post-test interpretation.
- If a relative has a confirmed variant, bring that report; it narrows the test and the interpretation.
Frequently Asked Questions
My relative has a confirmed PSEN1 variant. Should I test before my appointment?
Testing is reasonable, but the ACMG/NSGC guideline calls for formal pre-test counseling first, and DIAN-TU's staged design lets you enroll in Stage 1 before learning your status.
Will my APOE result from a consumer kit be accepted for Leqembi or Kisunla?
Possibly not. Lilly states that no FDA-authorized APOE ε4 test exists for this purpose and that available tests vary in accuracy, so expect a repeat through the prescriber's laboratory.
Can I start an anti-amyloid drug without APOE testing?
The Leqembi label says patients who decline may still be treated, but their homozygote status will be unknown — which removes the information behind the 32.6% versus 5.4% ARIA-E difference seen in CLARITY AD.
